Given the GEP results, we speculate that overlapping blockade of the BCR signaling pathway and reduction of antiapoptotic BCL2 underlie the combinatory antiproliferative effects in MCL cells harboring modest sensitivity to ibrutinib. The gene discussed is BCR; the disease is mantle cell lymphoma.